Is the Pharma Industry Facing Pharmageddon? Pfizer Inc. (PFE) and More

Page 1 of 2

The pharmaceuticals industry has always been one of the riskiest in the market. Companies operating in the pharma industry are required to invest heavily in research and development on drugs whose outcome is highly unpredictable. Companies like Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), and Johnson & Johnson (NYSE:JNJ) among others, have toiled this red flagged industry for years. Note that, despite the risks associated with investing in the industry, the potential upside is always enormous. No wonder, they say, “the higher the risk, the higher, the return.” But this is not always the case.

Pfizer Inc. (NYSE:PFE)What’s in this industry anyway?

The Pharma industry holds one of the biggest potential upsides across all sectors. Perhaps only Technology and Energy can compete on equal footing. Nonetheless, the attractiveness of this industry is yet the biggest peril for investors. Sounds like a paradox? Well, here is the deal. Some investors view the industry as next to gambling. Indeed, if a company, say Johnson & Johnson (NYSE:JNJ), manages to get things right and gets approval from Food and Drug Administration (FDA) to proceed with the licensing and the manufacture of a certain drug, then the returns are usually skewed to the right. The opposite is usually true.

A good example is the anticipated launch of three drugs by Pfizer, which have fuelled the demand for its stock, pushing it to a new five and a half-year high of $27.65, on February 1. The company received approval from FDA for its Rheumatoid Arthritis treatment available in pill form in November 2012, although it is yet to receive the marketing materials approval. It also received two more approvals in January.

Elsewhere, Johnson & Johnson is expected to improve significantly during the current campaign following the approval by FDA for a drug that is expected to treat a form of resistant tuberculosis that is uncommon in the U.S., but growing globally. On the other hand, Mylan Inc. (NASDAQ:MYL) is said to have received final approval from FDA for its Abbreviated New Drug Applications (ANDA) for Rizatriptan Benzoate Orally Disintegrating Tablets. The drug is a generic type of Merck’s Maxalt MLT and Maxalt tablets.

The Pharmageddon?

According to a report published by PriceWaterhouseCoopers (PWC) in November 2012, the pharma industry is expected to more than double its current value to the tune of $1.3 trillion by the year 2020. However, for large pharmas to romp in tandem with the industry, they are expected to change their game by diversifying their services and products, as the quandary of costs balloons to levels that could threaten disintegration. Indeed, this is already very evident with the rate of spin-offs already witnessed in the industry.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

Top 6 Cities For The Ultra Rich to Live in Comfort

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!